Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ERYtech Pharma has entered into an agreement with Teva to register, market, distribute and sell Graspa in Isreal.
Subscribe to our email newsletter
Graspa is a new enzyme formulation of L-asparaginase with a range of clinical uses compared to existing forms due to the enzymes entrapment and protection inside the homologous red blood cell.
The tie up allows Teva to lead regulatory procedures related to Graspa in Isreal as well as to market and distribute the product in the territory for a long period of time.
As per the terms of the agreement, ERYtech is entitled to get milestone payments from Teva and will also share profit on the basis of the price agreed with Teva.
ERYtech Pharma CEO Pierre-Olivier Goineau said this collaboration represents a milestone as first distribution agreement and a major step in the worldwide product expansion.
"Graspa, will bring major therapeutic value for Israeli patients in ALL," Goineau said.
ERYtech anticipates that first sales could be generated in less than 15 months.